<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855383</url>
  </required_header>
  <id_info>
    <org_study_id>FET-HCG</org_study_id>
    <nct_id>NCT04855383</nct_id>
  </id_info>
  <brief_title>Intramuscular Injection of Human Chorionic Gonadotropin in Frozen Embryo Transfer Cycles</brief_title>
  <official_title>The Effect of Intramuscular Injection of Triple Doses of Human Chorionic Gonadotropin in Frozen Embryo Transfer Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized controlled clinical trial to compare the pregnancy outcomes of&#xD;
      infertile women with frozen embryo transfer. The study population in frozen embryo transfer&#xD;
      cycles receive three doses of human chorionic gonadotropin (HCG) to recognize the&#xD;
      effectiveness of HCG on pregnancy outcomes in Reproductive Biomedicine Research Center, Royan&#xD;
      institute, Tehran Iran.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During implantation, the biochemical crosstalk between the endometrium and embryo has a very&#xD;
      important role. The endometrium secrets cytokines and growth factors that modulate embryonic&#xD;
      differentiation and early development. One of the important molecular messages between the&#xD;
      embryo and endometrium is human chorionic gonadotropin (HCG). HCG is expressed by the&#xD;
      blastocyst before the implantation, while increasingly produced after implantation by the&#xD;
      syncytiotrophoblast. In order to study the direct effect of HCG on the endometrium at&#xD;
      implantation, this randomized, controlled clinical trial evaluated whether HCG&#xD;
      supplementation would be beneficial for pregnancy outcomes of cryopreserved-thawed embryo&#xD;
      transfer with estrogen/ progesterone replacement cycles at Royan Institute.&#xD;
&#xD;
      Block randomization method is designed by epidemiologist using STATA software version 13 and&#xD;
      the number of blocks considered is 6. The random allocation list for patients is solely&#xD;
      available to the epidemiologist. In order to hide the random allocation process, a total of&#xD;
      200 envelopes are prepared, and only the methodologist has been aware of table of random&#xD;
      numbers. When the doctor declared the patient's eligibility, the methodologist provided the&#xD;
      doctor with the envelope. The group will be selected and based on the type of group mentioned&#xD;
      in the envelope.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">September 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>4 weeks after embryo transfer</time_frame>
    <description>The ratio of total number of observed gestational sacs to total number of transferred embryos.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>12 weeks after embryo transfer</time_frame>
    <description>Continued pregnancy at gestational week 12 or more per initiated cycle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>at least 20 weeks after embryo transfer</time_frame>
    <description>Live birth is defined in which a live fetus is delivered beyond 20 completed weeks of gestational.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Embryo Implantation</condition>
  <arm_group>
    <arm_group_label>The group of frozen embryo transfer with intramuscular injection of human chorionic gonadotropin.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The group of frozen embryo transfer without intramuscular injection of human chorionic gonadotropin.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Embryo transfer will be done without human chorionic gonadotropin intramuscular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles</intervention_name>
    <description>Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.</description>
    <arm_group_label>The group of frozen embryo transfer with intramuscular injection of human chorionic gonadotropin.</arm_group_label>
    <other_name>The effect of intramuscular injection of triple doses of human chorionic gonadotropin on embryo implantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Infertile women candidates for frozen embryo transfer Age 20-40 years Body Mass Index under&#xD;
        than 30 Kg/m2 Having at least three good quality embryos&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Women with hematologic and autoimmune disorders Couples with chromosomal and genetic&#xD;
        abnormalities Women with uterine anomalies Women with uterine and ovaries surgical history&#xD;
        Women with endometriosis and adenomyosis Women with hydrosalpinx Women with uterine&#xD;
        fibroids Women with history of recurrent abortion or recurrent implantation failure Severe&#xD;
        male factor infertility (azoospermia) Embryo donation cycle Endometrial thickness less than&#xD;
        8 millimeter on the day of embryo transfer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehri Mashayekhi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Endocrinology and Female Infertility, ACECR, Tehran, Iran.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azar Yahyaei, M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology and Female Infertility, ACECR, Tehran, Iran.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parvaneh Afsharian, PhD</last_name>
    <phone>+982123562674</phone>
    <email>pafshar@royaninstitute.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <zip>16635-148</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parvaneh Afsharian, PhD</last_name>
      <phone>+982123562674</phone>
      <email>pafshar@royaninstitute.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 18, 2021</last_update_submitted>
  <last_update_submitted_qc>April 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human chorionic gonadotropin</keyword>
  <keyword>frozen embryo transfer</keyword>
  <keyword>infertility</keyword>
  <keyword>assisted reproduction technology</keyword>
  <keyword>estrogen/ progesterone replacement cycles</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the publication of the article Available to the public. Scientific use by citing the source. Request via e-mail</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After the publication of the article</ipd_time_frame>
    <ipd_access_criteria>Available to the public. Scientific use by citing the source.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

